CYH
Community Health Systems, Inc.
CYH trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CYH overall, supported by lower modeled downside and stronger modeled upside.
CYH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
CYH's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CYH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.3x | $0.35 | -84% |
| Fair | 2x | $0.55 | -75% |
| Expensive | 4.4x | $1.18 | -47% |
| Current | 8.2x | $2.21 | — |
Historical ranges are pointers, not guarantees.
CYH's PE is in its expensive range at 8.2x.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over CYH in the historical PE scenario, which offers more potential upside but is not a forecast.
CYH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CYH's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CYH on the outlook, with more favorable earnings and revenue expectations.
CYH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.27 | -89% |
| Q2 2026 | $1.86 | +$3.35 |
| Q1 2026 | $3.44 | +$7.12 |
| Q4 2025 | $3.77 | +$7.67 |
| Q3 2025 | $2.42 | +$5.43 |
| Q2 2025 | -$1.49 | -$0.74 |
| Q1 2025 | -$3.68 | -$2.74 |
| Q4 2024 | -$3.90 | -$2.88 |
CYH's earnings per share have fallen from their peak: $0.27 over the past year, against $4.39 in late 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CYH on earnings, with more consistent year-over-year improvement.
CYH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | -11% |
| Q2 2026 | $2.8B | -9.8% |
| Q1 2026 | $3B | -6.1% |
| Q4 2025 | $3.1B | -4.9% |
| Q3 2025 | $3.1B | -0.1% |
| Q2 2025 | $3.1B | -0.2% |
| Q1 2025 | $3.2B | +0.6% |
| Q4 2024 | $3.3B | +2.6% |
CYH's revenue has slid since its 2019 peak: $2.8B last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.3% | -2.6 points |
| Q2 2026 | 14% | -2.6 points |
| Q1 2026 | 9.5% | +0.5 points |
| Q4 2025 | 14% | +6 points |
| Q3 2025 | 7.9% | +15 points |
| Q2 2025 | 16% | +8.8 points |
| Q1 2025 | 9% | +1.6 points |
| Q4 2024 | 8.5% | -1.8 points |
CYH's operating margin was 5.3% last quarter, down 2.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CYH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CYH on profitability, with a higher operating margin.
CYH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67M | +1575% |
| Q2 2026 | $12M | +$15M |
| Q1 2026 | -$373M | -1166% |
| Q4 2025 | $172M | +61% |
| Q3 2025 | $4M | +$7M |
| Q2 2025 | -$3M | -123% |
| Q1 2025 | $35M | +1067% |
| Q4 2024 | $107M | +$127M |
CYH's free cash flow was −$122M over the past year, against $143M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CYH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -963K shares |
| 1 year | +0.3% | +355K shares |
| 3 years | +3.7% | +4.8M shares |
| 5 years | +3.6% | +4.7M shares |
| Available history | +19% | +21.6M shares |
CYH has 136M diluted shares, about the same as a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CYH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CYH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.5x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 4.9x | High |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.9x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 10.2x | High |
| Q4 2024 | 11.1x | High |
CYH's net debt is about 5.5 years of its operating earnings (EBITDA), down from 5.9 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CYH on leverage, with a lower net debt burden relative to earnings.
CYH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 19.0 | Oversold |
CYH's weekly RSI is 34 (neutral) and its Stochastic is 19 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CYH PE vs Healthcare Sector
| Metric | CYH | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 92 | 29 | 63 pts above |
CYH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CYH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.63 | 16% below |
| 20 week MA | $2.90 | 24% below |
| 50 week MA | $3.03 | 27% below |
| 100 week MA | $3.09 | 28% below |
| 200 week MA | $3.55 | 38% below |
CYH is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CYH on trend strength, trading above more of its moving averages.
CYH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.77 | $7.67 | +177% |
| 2021 | $7.67 | $13.3 | +73% |
| 2022 | $13.3 | $3.88 | -71% |
| 2023 | $3.88 | $3.13 | -19% |
| 2024 | $3.13 | $3.03 | -3.2% |
| 2025 | $3.03 | $3.23 | +6.6% |
| 2026 YTD | $3.23 | $2.21 | -32% |
CYH's yearly returns have swung widely, from +177% in 2020 to −71% in 2022. It's down 32% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CYH on returns for 2026, with the stronger performance.